|Videos|March 23, 2023
Discussion of Traditional and Novel GPP Treatment Modalities
Author(s)Michael Payette, MD, MBA, FAAD
An expert in dermatology shares his insights into the management considerations with traditionally utilized treatments for generalized pustular psoriasis and discusses the impact of a recent approval in this space.
Advertisement
Episodes in this series
Advertisement
Related to this article
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
FDA Revises TB Evaluation Guidance for SKYRIZI
3
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
4
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
5